Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with
valvular heart disease (VHD) is also common. However, management strategies for this …

Despite the same electrophysiological abnormality, the risk of stroke and systemic embolism
in atrial fibrillation (AF) ranges from, 1%/year to. 20%/year and can be assessed by simple …

Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

Komisję ESC ds. Wytycznych Postępowania nadzoruje i koordynuje przygotowywanie
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …

Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

Se recomienda a los profesionales de la salud que tengan en consideración la presente
guía de la ESC/EACTS en la toma de decisiones clínicas en su ejercicio diario, así como en …

Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials comparing vitamin K
antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in AF were …

Background: The use of non-vitamin K antagonist oral anticoagulants (NOACs) instead of
vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular …

Aims Left atrial appendage (LAA) occlusion has emerged as an interesting alternative to oral
anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). We report …

Background: Patients with mitral stenosis and atrial fibrillation (AF) require anticoagulation
for stroke prevention. Thus far, all studies on direct oral anticoagulants (DOACs) have …